Safety and immunogenicity of 17DD attenuated yellow fever vaccine in howler monkeys (Alouatta spp.)

Background Alouatta spp. are highly susceptible to yellow fever (YF) infection and develop an often fatal disease. The threat posed by an outbreak started in 2016 leads us to investigate vaccination as a potential tool in preventing YF in non‐human primates (NHP). Methods Susceptible howler monkeys...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medical primatology 2021-02, Vol.50 (1), p.36-45
Main Authors: Tavares da Silva Fernandes, André, Moreira, Silvia Bahadian, Gaspar, Luciane Pinto, Simões, Marisol, Cajaraville, Ana Carolina dos Reis Albuquerque, Pereira, Renata Carvalho, Gomes, Mariana Pierre de Barros, Linhares, José Henrique Rezende, Santos, Vanessa de Oliveira, Santos, Renata Tourinho, Amorim, Juliana Fernandes, Barros, Tamiris Azamor da Costa, Melgaço, Juliana Gil, Silva, Andréa Marques Vieira, Fernandes, Camilla Bayma, Tubarão, Luciana Neves, Silva, Jane, Caride, Elena Cristina, Borges, Maria Beatriz, Guimarães, Rosane Cuber, Marchevsky, Renato Sérgio, Lima, Sheila Maria Barbosa, Ano Bom, Ana Paula Dinis, Neves, Patrícia Cristina da Costa, Pissinatti, Alcides, Freire, Marcos da Silva
Format: Article
Language:English
Subjects:
Alouatta
Atelidae
Endangered species
epizootic
Epizootics
howler monkey
Immune response (humoral)
Immunization
Immunogenicity
monkey immunization
Monkeys & apes
sentinel monkey
Vaccination
vaccine efficacy
Vaccines
Viremia
virus
Yellow fever
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Alouatta spp. are highly susceptible to yellow fever (YF) infection and develop an often fatal disease. The threat posed by an outbreak started in 2016 leads us to investigate vaccination as a potential tool in preventing YF in non‐human primates (NHP). Methods Susceptible howler monkeys were immunized with three different concentrations of the human Brazilian commercial YF17DD vaccine. Post‐vaccination viremia/RNAemia, immunogenicity, and safety were characterized. Results The vaccine did not produce YF clinical manifestations in any of the NHPs. After immunization, all animals seroconverted demonstrating the ability of the YF vaccine to induce humoral response in Alouatta species. Conclusions The present work has demonstrated the safe and immunogenic profile of the existing YF 17DD vaccine in howler monkeys. This knowledge may support further studies with other susceptible monkey species and provide a possible solution for controlling epizootics and preventing the devastation of endangered species.
ISSN:0047-2565
1600-0684
DOI:10.1111/jmp.12501